問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Urology

更新時間：2023-09-19

李香瑩Lee, Hsiang Ying
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

21Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李香瑩

List

34Cases

2020-05-18 - 2023-12-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women

  • Condition/Disease

    Recurrent Urinary Tract Infections (rUTIs)

  • Test Drug

    U101

Participate Sites
19Sites

Not yet recruiting7Sites

Recruiting6Sites

Terminated6Sites

2022-02-01 - 2026-03-30

Phase I/II

Active
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

  • Condition/Disease

    Urothelial Carcinoma

  • Test Drug

    皮下注射劑 皮下注射劑

Participate Sites
4Sites

Recruiting4Sites

2016-08-01 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-12-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-06-01 - 2030-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2019-06-01 - 2024-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2023-12-01 - 2029-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2015-11-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-12-17 - 2030-08-23

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2031-07-31

Phase III

Active
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator’s Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Prostate cancer

  • Test Drug

    Frozen Crystal Injection Injection Injection Lumps Lumps Lumps

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB